A C. elegans model of C9orf72-associated ALS/FTD uncovers a conserved role for eIF2D in RAN translation

被引:0
|
作者
Yoshifumi Sonobe
Jihad Aburas
Gopinath Krishnan
Andrew C. Fleming
Ghanashyam Ghadge
Priota Islam
Eleanor C. Warren
Yuanzheng Gu
Mark W. Kankel
André E. X. Brown
Evangelos Kiskinis
Tania F. Gendron
Fen-Biao Gao
Raymond P. Roos
Paschalis Kratsios
机构
[1] University of Chicago Medical Center,Department of Neurology
[2] University of Chicago Medical Center,The Grossman Institute for Neuroscience, Quantitative Biology, and Human Behavior
[3] University of Chicago,Department of Neurobiology
[4] University of Chicago,Department of Neurology
[5] University of Massachusetts Medical School,The Ken & Ruth Davee Department of Neurology, Feinberg School of Medicine
[6] Northwestern University,Institute of Clinical Sciences
[7] MRC London Institute of Medical Sciences,Department of Neuroscience
[8] Imperial College London,undefined
[9] Neuromuscular & Movement Disorders,undefined
[10] Biogen,undefined
[11] Mayo Clinic,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
A hexanucleotide repeat expansion GGGGCC in the non-coding region of C9orf72 is the most common cause of inherited amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Toxic dipeptide repeats (DPRs) are synthesized from GGGGCC via repeat-associated non-AUG (RAN) translation. Here, we develop C. elegans models that express, either ubiquitously or exclusively in neurons, 75 GGGGCC repeats flanked by intronic C9orf72 sequence. The worms generate DPRs (poly-glycine-alanine [poly-GA], poly-glycine-proline [poly-GP]) and poly-glycine-arginine [poly-GR]), display neurodegeneration, and exhibit locomotor and lifespan defects. Mutation of a non-canonical translation-initiating codon (CUG) upstream of the repeats selectively reduces poly-GA steady-state levels and ameliorates disease, suggesting poly-GA is pathogenic. Importantly, loss-of-function mutations in the eukaryotic translation initiation factor 2D (eif-2D/eIF2D) reduce poly-GA and poly-GP levels, and increase lifespan in both C. elegans models. Our in vitro studies in mammalian cells yield similar results. Here, we show a conserved role for eif-2D/eIF2D in DPR expression.
引用
收藏
相关论文
共 50 条
  • [21] Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in C9orf72 Mouse Model
    Nguyen, Lien
    Montrasio, Fabio
    Pattamatta, Amrutha
    Tusi, Solaleh Khoramian
    Bardhi, Olgert
    Meyer, Kevin D.
    Hayes, Lindsey
    Nakamura, Katsuya
    Banez-Coronel, Monica
    Coyne, Alyssa
    Guo, Shu
    Laboissonniere, Lauren A.
    Gu, Yuanzheng
    Narayanan, Saravanakumar
    Smith, Benjamin
    Nitsch, Roger M.
    Kankel, Mark W.
    Rushe, Mia
    Rothstein, Jeffrey
    Zu, Tao
    Grimm, Jan
    Ranum, Laura P. W.
    NEURON, 2020, 105 (04) : 645 - +
  • [22] Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice
    Zu, Tao
    Guo, Shu
    Bardhi, Olgert
    Ryskamp, Daniel A.
    Li, Jian
    Tusi, Solaleh Khoramian
    Engelbrecht, Avery
    Klippel, Kelena
    Chakrabarty, Paramita
    Nguyen, Lien
    Golde, Todd E.
    Sonenberg, Nahum
    Ranum, Laura P. W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (31) : 18591 - 18599
  • [23] Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD
    Liu, Yuanjing
    Andreucci, Amy
    Iwamoto, Naoki
    Yin, Yuan
    Yang, Hailin
    Liu, Fangjun
    Bulychev, Alexey
    Hu, Xiao Shelley
    Lin, Xuena
    Lamore, Sarah
    Patil, Saurabh
    Mohapatra, Susovan
    Purcell-Estabrook, Erin
    Taborn, Kristin
    Dale, Elena
    Vargeese, Chandra
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2022, 28 : 558 - 570
  • [24] Targeting ran proteins improves phenotypes in C9orf72 BAC ALS/FTD mice
    Ranum, L.
    Nguyen, L.
    Montrasio, F.
    Bardhi, O.
    Guo, S.
    Tusi, S. K.
    Nakamura, K.
    Coronel, M. B.
    Sonenberg, N.
    Grimm, J.
    Zu, T.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 44 - 44
  • [25] Unraveling the impact of disrupted nucleocytoplasmic transport systems in C9orf72-associated ALS
    Mcgoldrick, Philip
    Robertson, Janice
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2023, 17
  • [26] Role of C9orf72 hexanucleotide repeat expansions in ALS/FTD pathogenesis
    Geng, Yanyan
    Cai, Qixu
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2024, 17
  • [27] A neuroprotective role of polyunsaturated fatty acids in C9orf72-ALS/FTD
    Dubey, Sandeep Kumar
    Bellen, Hugo J.
    NATURE NEUROSCIENCE, 2025, : 710 - 712
  • [28] Cognitive Endophenotype Associated with the C9ORF72 GGGGCC Expansion in FTD/ALS
    Pedraza, Otto
    Boeve, Bradley
    DeJesus-Hernandez, Mariely
    Rush, Beth
    Lucas, John
    Fields, Julie
    Machulda, Mary
    Graff-Radford, Neill
    Knopman, David
    Josephs, Keith
    Rutherford, Nicola
    Baker, Matthew
    Ferman, Tanis
    Smith, Glenn
    Ivnik, Robert
    Wszolek, Zbigniew
    Boylan, Kevin
    Petersen, Ronald
    Rademakers, Rosa
    NEUROLOGY, 2012, 78
  • [29] The Role of Dipeptide Repeats in C9ORF72-Related ALS-FTD
    Freibaum, Brian D.
    Taylor, J. Paul
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2017, 10
  • [30] Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD
    Lehmer, Carina
    Oeckl, Patrick
    Weishaupt, Jochen H.
    Volk, Alexander E.
    Diehl-Schmid, Janine
    Schroeter, Matthias L.
    Lauer, Martin
    Kornhuber, Johannes
    Levin, Johannes
    Fassbender, Klaus
    Landwehrmeyer, Bernhard
    Schludi, Martin H.
    Arzberger, Thomas
    Kremmer, Elisabeth
    Flatley, Andrew
    Feederle, Regina
    Steinacker, Petra
    Weydt, Patrick
    Ludolph, Albert C.
    Edbauer, Dieter
    Otto, Markus
    EMBO MOLECULAR MEDICINE, 2017, 9 (07) : 859 - 868